Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS
· Delayed Price · Currency is USD
0.0225
0.00 (0.00%)
Sep 26, 2024, 11:00 AM EDT
Oncotelic Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 0.07 | 0.07 | - | - | 1.74 | - | Upgrade
|
| Gross Profit | 0.07 | 0.07 | - | - | 1.74 | - | Upgrade
|
| Selling, General & Admin | 0.4 | 0.57 | 4.85 | 5.47 | 5.02 | 2.94 | Upgrade
|
| Research & Development | 0.03 | 0.06 | 0.76 | 3.66 | 4.3 | 1.37 | Upgrade
|
| Operating Expenses | 0.43 | 0.63 | 5.61 | 9.13 | 9.33 | 4.31 | Upgrade
|
| Operating Income | -0.36 | -0.56 | -5.61 | -9.13 | -7.58 | -4.31 | Upgrade
|
| Interest Expense | -0.84 | -1.04 | -2.97 | -2 | -2 | -0.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.15 | -0.15 | 0.68 | 0.29 | -0.05 | 0.19 | Upgrade
|
| EBT Excluding Unusual Items | -1.05 | -1.76 | -7.91 | -10.84 | -9.63 | -4.87 | Upgrade
|
| Impairment of Goodwill | - | -6.08 | -4.11 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.01 | 0.01 | - | - | - | -1.77 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 16.95 | - | - | - | Upgrade
|
| Other Unusual Items | -0.46 | -0.37 | -0.26 | 0.32 | -0.34 | - | Upgrade
|
| Pretax Income | -1.5 | -8.21 | 4.68 | -10.52 | -9.97 | -6.64 | Upgrade
|
| Earnings From Continuing Operations | -1.5 | -8.21 | 4.68 | -10.52 | -9.97 | -6.64 | Upgrade
|
| Minority Interest in Earnings | 0.26 | 0.3 | 0.42 | 1.13 | 0.47 | - | Upgrade
|
| Net Income | -1.24 | -7.9 | 5.09 | -9.39 | -9.5 | -6.64 | Upgrade
|
| Net Income to Common | -1.24 | -7.9 | 5.09 | -9.39 | -9.5 | -6.64 | Upgrade
|
| Shares Outstanding (Basic) | 400 | 396 | 384 | 303 | 88 | 60 | Upgrade
|
| Shares Outstanding (Diluted) | 400 | 396 | 457 | 303 | 88 | 60 | Upgrade
|
| Shares Change (YoY) | 2.12% | -13.37% | 50.88% | 244.02% | 46.93% | 877.11% | Upgrade
|
| EPS (Basic) | -0.00 | -0.02 | 0.01 | -0.03 | -0.11 | -0.11 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.02 | 0.01 | -0.03 | -0.11 | -0.11 | Upgrade
|
| Free Cash Flow | -1.11 | -1.32 | -1.45 | -4.43 | -2.81 | -2.28 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | -0.01 | -0.03 | -0.04 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | - | - | 100.00% | - | Upgrade
|
| Operating Margin | -518.27% | -806.96% | - | - | -435.69% | - | Upgrade
|
| Profit Margin | -1770.27% | -11290.13% | - | - | -545.86% | - | Upgrade
|
| Free Cash Flow Margin | -1592.37% | -1887.21% | - | - | -161.53% | - | Upgrade
|
| EBITDA | - | -0.55 | -5.6 | -9.06 | -7.22 | -4.25 | Upgrade
|
| D&A For EBITDA | - | 0.01 | 0.01 | 0.06 | 0.36 | 0.06 | Upgrade
|
| EBIT | -0.36 | -0.56 | -5.61 | -9.13 | -7.58 | -4.31 | Upgrade
|
| Revenue as Reported | 0.07 | 0.07 | - | - | 1.74 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.